Filtered By:
Source: Skin and Allergy News
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 905 results found since Jan 2013.
Ebola patients treated in the West showed 81.5% survival
Overall survival was 81.5% for the 27 patients with Ebola virus infection who were treated in the United States or Europe during the recent outbreak, according to a report published online Feb. 18 in the New England Journal of Medicine.
This is markedly higher than the 37%-74% survival reported...
Source: Skin and Allergy News - February 17, 2016 Category: Dermatology Source Type: news
Change to NPDB guidebook redefines ‘investigation’
AUSTIN, TEX. – Physicians could face more reportable actions to the National Practitioner Data Bank (NPDB) under changes to the data bank’s guidebook.
In its last update of the guidebook, the Health Resources and Services Administration (HRSA) expanded its definition of “investigation” and now...
Source: Skin and Allergy News - February 17, 2016 Category: Dermatology Source Type: news
Doctors, payers collaborate to simplify and align quality measures
The Centers for Medicare & Medicaid Services and America’s Health Insurance Plans on Feb 16 announced a set of core quality measures across seven areas that will serve as the foundation for a more uniform set of quality metrics that will be used by both public and private payers.
The CMS and...
Source: Skin and Allergy News - February 17, 2016 Category: Dermatology Source Type: news
VIDEO: Which patients are best for new onychomycosis topicals?
WAIKOLOA, HAWAII – Two new topical treatments for nail fungal infections are more effective than previous topical therapies, but the key to successful results is picking the right onychomycosis patient, according to Dr. Theodore Rosen.
The two new agents, tavaborole and efinaconazole, “are both...
Source: Skin and Allergy News - February 17, 2016 Category: Dermatology Source Type: news
Elevated cardiovascular risks linked to hidradenitis suppurativa
The inflammatory skin disease hidradenitis suppurativa is associated with significantly increased risks of adverse cardiovascular outcomes such as ischemic stroke, myocardial infarction, and cardiovascular mortality, according to results of a population-based study.
A population-based cohort study...
Source: Skin and Allergy News - February 17, 2016 Category: Dermatology Source Type: news
VIDEO: New topical acne therapies will target sebum
WAIKOLOA, HAWAII – Three new approaches to topical treatment of acne are on the horizon, and they all share a common foe: sebum.
“One exciting new avenue for topical therapy are drugs that actually target the production of sebum,” explained Dr. Linda F. Stein Gold, director of dermatology research...
Source: Skin and Allergy News - February 17, 2016 Category: Dermatology Source Type: news
VIDEO: What’s new on atopic dermatitis drugs and cancer concerns?
WAIKOLOA, HAWAII – Topical calcineurin inhibitors’ boxed warnings give many patients and physicians pause over cancer concerns – but a new database analysis may put some minds at ease about the drugs’ use for atopic dermatitis.
“Pimecrolimus and tacrolimus are given topically, not internally –...
Source: Skin and Allergy News - February 17, 2016 Category: Dermatology Source Type: news
VIDEO: IL-17 antagonists continue reshaping psoriasis therapy in 2016
WAIKOLOA, HAWAII – What’s going to be the biggest development in the field of psoriasis in 2016?
Hint: Look for a repeat of 2015.
The first of the interleukin-17 antagonists, secukinumab, was the biggest development of 2015, explained Dr. Craig L. Leonardi, associate clinical professor of...
Source: Skin and Allergy News - February 15, 2016 Category: Dermatology Source Type: news
CMS clarifies how to report Medicare overpayments
There is finally some clarity about how to report and return Medicare overpayments, under a final rule released by the Centers for Medicare & Medicaid Services Feb. 11.
The final regulation clarifies...
Source: Skin and Allergy News - February 12, 2016 Category: Dermatology Source Type: news
CMS extends deadline for 2015 EHR attestation
Physicians and hospitals will have an extra 2 weeks to attest to meaningful use of electronic health records in 2015.
Source: Skin and Allergy News - February 12, 2016 Category: Dermatology Source Type: news
Dermatologic features may help distinguish Zika infection
Dermatologists may be seeing patients who have recently traveled to an area affected by the current Zika outbreaks, who present with a rash and possibly a fever.
Source: Skin and Allergy News - February 11, 2016 Category: Dermatology Source Type: news
Borrelia mayonii is new cause of Lyme disease variant
A new species of Borrelia has been linked to a variant of Lyme disease with symptoms that differ somewhat from typical Lyme borreliosis.
Of 100,545 routine clinical specimens tested at the Mayo Clinic in Rochester, Minn., for Lyme borreliosis between 2003 and 2014, six clinical specimens –...
Source: Skin and Allergy News - February 11, 2016 Category: Dermatology Source Type: news
Mechanism for dust mite–triggered atopic dermatitis identified
Researchers have identified a possible mechanism by which house dust mites could trigger the development of atopic dermatitis in individuals with a genetic predisposition.
The study, published online Feb. 10 in Science Translational Medicine, took skin and blood samples from individuals with...
Source: Skin and Allergy News - February 10, 2016 Category: Dermatology Source Type: news
House panel says Medicare biosimilar payment plan will stifle innovation
Questions linger as to whether federal health care payment policies will encourage – or stifle – the entry of more biosimilars into the marketplace.
Getting the biosimilar approval process right “doesn’t matter unless we get the charging/reimbursement process right,” Rep. Joe Barton (R-Tex.),...
Source: Skin and Allergy News - February 10, 2016 Category: Dermatology Source Type: news
Biosimilar infliximab gains FDA Advisory Committee endorsement
A biosimilar agent to Remicade, the brand-name and reference form of infliximab, stayed on track to become the second biosimilar drug to enter the U.S. market when the Arthritis Advisory Committee of the Food and Drug Administration voted overwhelmingly in...
Source: Skin and Allergy News - February 10, 2016 Category: Dermatology Source Type: news
